Ocupress

   
Google
 
Web NewDrugInformation.com

Ocupress


Drug - Ocupress
The trade name of the product as shown on the labeling.

Dosage - SOLUTION/DROPS; OPHTHALMIC
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Carteolol Hydrochloride
Multiple ingredients are in alphabetical order.

Strength - 1%
The potency of the active ingredient(s), Carteolol Hydrochloride. May repeat for multiple part products.

Applicant - NOVARTIS
The firm name holding legal responsibility for Ocupress. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 019972
The FDA assigned number to Ocupress. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Ocupress. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code - AT
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - May 23, 1990
The date Ocupress was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - Yes
The pioneer or innovator of Ocupress. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Ocupress is in. Format is RX, OTC, DISCN.

Applicant Full Name - Novartis Pharmaceuticals Corp
The full name of the firm holding legal responsibility for the new application of Ocupress.

Ocupress